Her move follows the company’s revenue for 1HFY21 ended June which was “in line with our forecasts”.
SAC Capital is maintaining its “buy” call and target price of 37 cents on pharmaceutical distributor Hyphens Pharma.
The price translates to an FY21 Price-to-earnings (P/E) of 17.5x and is expected to give the counter a 23.3% upside from its 30 cent price, analyst Tracy Lim writes in a Aug 24 report.
